share_log

艾美疫苗：截至二零二四年三月三十一日止之股份發行人的證券變動月報表

AIM VACCINE: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024

香港交易所 ·  Apr 3 05:02
Summary by Moomoo AI
艾美疫苗股份有限公司於2024年4月3日向香港交易及結算所有限公司提交了最新的證券變動月報表，報告截至2024年3月31日的股本變動情況。報告顯示，艾美疫苗的H股和內資股在過去一個月內均無增減，H股結存數目維持在492,173,711股，而內資股結存數目則為718,888,888股。此外，根據艾美疫苗的股份期權計劃，截至本月底，公司擬發行的普通股可能是H股或內資股，並無新增股份期權發行，結存的股份期權數目為10,920,000。公司確認所有證券發行均已獲董事會批准，並符合香港聯合交易所有限公司證券上市規則的相關要求。
艾美疫苗股份有限公司於2024年4月3日向香港交易及結算所有限公司提交了最新的證券變動月報表，報告截至2024年3月31日的股本變動情況。報告顯示，艾美疫苗的H股和內資股在過去一個月內均無增減，H股結存數目維持在492,173,711股，而內資股結存數目則為718,888,888股。此外，根據艾美疫苗的股份期權計劃，截至本月底，公司擬發行的普通股可能是H股或內資股，並無新增股份期權發行，結存的股份期權數目為10,920,000。公司確認所有證券發行均已獲董事會批准，並符合香港聯合交易所有限公司證券上市規則的相關要求。
EMERY VACCINES CO., LTD. FILED ITS LATEST MONTHLY SECURITIES FLUCTUATION REPORT WITH HONG KONG TRADING AND SETTLEMENT LIMITED ON APRIL 3, 2024, REPORTING CHANGES IN SHARE CAPITAL AS OF MARCH 31, 2024. The report showed that both the H-shares and the Inward Equity in the last month remained unchanged, with the number of H-shares outstanding at 492,173,711 shares and the number of equity holdings at 718,888,888 shares. In addition, as of the end of this month, the Company's proposed common shares may be H-shares or equity shares, without the issuance of additional share options, and the number of outstanding share options is 10,920,000, according to the stock option plan of EME Vaccine. The Company confirms that all securities issues have been approved by the Board of Directors and comply with the relevant requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited.
EMERY VACCINES CO., LTD. FILED ITS LATEST MONTHLY SECURITIES FLUCTUATION REPORT WITH HONG KONG TRADING AND SETTLEMENT LIMITED ON APRIL 3, 2024, REPORTING CHANGES IN SHARE CAPITAL AS OF MARCH 31, 2024. The report showed that both the H-shares and the Inward Equity in the last month remained unchanged, with the number of H-shares outstanding at 492,173,711 shares and the number of equity holdings at 718,888,888 shares. In addition, as of the end of this month, the Company's proposed common shares may be H-shares or equity shares, without the issuance of additional share options, and the number of outstanding share options is 10,920,000, according to the stock option plan of EME Vaccine. The Company confirms that all securities issues have been approved by the Board of Directors and comply with the relevant requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more